Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Changes in Health-Related Quality of Life Corresponding to Hematologic Responses to Treatment in AL Amyloidosis

Vaishali Sanchorawala, MD, Kristen McCausland, Stephen Lo, Michelle K. White, PhD, Martha Bayliss, Spencer D. Guthrie, MBA, Colin Oliver, PhD MBA, Martha Skinner

Blood (2016) 128 (22): 3586.

https://doi.org/10.1182/blood.V128.22.3586.3586

Published: 2016

Journal Articles

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Stephanie B. Tsai, David C. Seldin, Karen Quillen, John L. Berk, Frederick L. Ruberg, Hans Meier-Ewert, J. Mark Sloan, Gheorghe Doros, Kathleen T. Finn, Martha Skinner, Vaishali Sanchorawala

Blood (2012) 120 (22): 4445–4446.

https://doi.org/10.1182/blood-2012-09-457341

Published: 2012

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

Maria Teresa Cibeira, Vaishali Sanchorawala, David C. Seldin, Karen Quillen, John L. Berk, Laura M. Dember, Adam Segal, Frederick Ruberg, Hans Meier-Ewert, Nancy T. Andrea, J. Mark Sloan, Kathleen T. Finn, Gheorghe Doros, Joan Blade, Martha Skinner

Blood (2011) 118 (16): 4346–4352.

https://doi.org/10.1182/blood-2011-01-330738

Published: 2011

Journal Articles

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Vaishali Sanchorawala, MD, Karen Quillen, MD, MPH, Kathleen T Finn, ANP, Nancy T Andrea, MD, J. Mark Sloan, MD, Laura Dember, MD, Adam Segal, MD, Gheorghe Doros, PhD, Martha Skinner, MD, David Seldin, MD

Blood (2010) 116 (21): 3553.

https://doi.org/10.1182/blood.V116.21.3553.3553

Published: 2010

Journal Articles

Macroglossia – Not Always AL Amyloidosis

Andrew J Cowan, MD, Martha Skinner, MD, J. Mark Sloan, MD, John L Berk, MD, Carl J O'Hara, MD, David C Seldin, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 5007.

https://doi.org/10.1182/blood.V116.21.5007.5007

Published: 2010

Journal Articles

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

M. Teresa Cibeira, MD, PhD, Vaishali Sanchorawala, MD, David C Seldin, MD, PhD, Karen Quillen, MD, MPH, Nancy Andrea, MD, J. Mark Sloan, MD, Kathleen T Finn, ANP, John L Berk, MD, Gheorghe Doros, PhD, Joan Blade, Martha Skinner, MD

Blood (2010) 116 (21): 2394.

https://doi.org/10.1182/blood.V116.21.2394.2394

Published: 2010

Journal Articles

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Saulius Girnius, MD, Frank Tsai, MD, David C. Seldin, MD, PhD, Karen Quillen, MD, Lisa Yanarella, NP, Kathleen T. Finn, NP, Nancy T. Andrea, MD, John Mark Sloan, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4352.

https://doi.org/10.1182/blood.V114.22.4352.4352

Published: 2009

Journal Articles

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, John Mark Sloan, MD, John L. Berk, MD, Martha Skinner

Blood (2009) 114 (22): 1883.

https://doi.org/10.1182/blood.V114.22.1883.1883

Published: 2009

Journal Articles

Localized AL Amyloidosis of the Breast: A Case Series.

Marjory Charlot, MD, David C. Seldin, MD, PhD, Carl O'Hara, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2009) 114 (22): 4906.

https://doi.org/10.1182/blood.V114.22.4906.4906

Published: 2009

Journal Articles

Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall” Reaction.

Michael Rosenzweig, David C. Seldin, Daniel G Remick, Martha Skinner, Karen Quillen, Betul Oran, Kathleen T. Finn, Vaishali Sanchorawala

Blood (2008) 112 (11): 1120.

https://doi.org/10.1182/blood.V112.11.1120.1120

Published: 2008

Journal Articles

Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution

Vaishali Sanchorawala, MD, Martha Skinner, Kathleen T. Finn, Karen Quillen, David C. Seldin

Blood (2008) 112 (11): 53.

https://doi.org/10.1182/blood.V112.11.53.53

Published: 2008

Journal Articles

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Saulius Girnius, MD, David C. Seldin, MD, PhD, Martha Skinner, MD, Kathleen T. Finn, NP, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 2873.

https://doi.org/10.1182/blood.V110.11.2873.2873

Published: 2007

Journal Articles

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

David C. Seldin, MD, PhD, Michael Rosenzweig, MD, Kathleen T. Finn, RN, NP, Salli Fennessey, Anthony Shelton, Jerome B. Zeldis, MD, Martha Skinner, MD, Vaishali Sanchorawala, MD

Blood (2007) 110 (11): 192.

https://doi.org/10.1182/blood.V110.11.192.192

Published: 2007

Journal Articles

Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure.

Bimalangshu R. Dey, MD, PhD, Thomas R. Spitzer, MD, Thomas E. MacGillivray, MD, Stephen S. Chung, MD, G.W. Dec, MD, David C. Seldin, MD, Steven L. McAfee, MD, Karen Ballen, MD, Eyal Attar, MD, Martha Skinner, MD, Joren C. Madsen, MD, DPhil, Marc J. Semigran, MD

Blood (2007) 110 (11): 732.

https://doi.org/10.1182/blood.V110.11.732.732

Published: 2007

Journal Articles

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Vaishali Sanchorawala, Martha Skinner, Karen Quillen, Kathleen T. Finn, Gheorghe Doros, David C. Seldin

Blood (2007) 110 (10): 3561–3563.

https://doi.org/10.1182/blood-2007-07-099481

Published: 2007

Journal Articles

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65

David C. Seldin, Jennifer J. Anderson, Martha Skinner, Karim Malek, Daniel G. Wright, Karen Quillen, Kathleen Finn, Betul Oran, Vaishali Sanchorawala

Blood (2006) 108 (12): 3945–3947.

https://doi.org/10.1182/blood-2006-06-029728

Published: 2006

Journal Articles

Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

David C. Seldin, MD, PhD, Martha Skinner, MD, Betul Oran, MD, Karen Quillen, MD, Kathleen T. Finn, RN, NP, Vaishali Sanchorawala, MD

Blood (2006) 108 (11): 3094.

https://doi.org/10.1182/blood.V108.11.3094.3094

Published: 2006

Journal Articles

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Vaishali Sanchorawala, MD, Daniel G. Wright, MD, Karen Quillen, MD, Laura M. Dember, MD, John L. Berk, MD, Kathleen T. Finn, RN, Martha Skinner, MD, David C. Seldin, MD, PhD

Blood (2006) 108 (11): 612.

https://doi.org/10.1182/blood.V108.11.612.612

Published: 2006

Journal Articles

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

Vaishali Sanchorawala, Daniel G. Wright, Michael Rosenzweig, Kathleen T. Finn, Salli Fennessey, Jerome B. Zeldis, Martha Skinner, David C. Seldin

Blood (2006) 109 (2): 492–496.

https://doi.org/10.1182/blood-2006-07-030544

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Changes in Health-Related Quality of Life Corresponding to Hematologic Responses to Treatment in AL Amyloidosis

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis

Macroglossia – Not Always AL Amyloidosis

Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients

Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Localized AL Amyloidosis of the Breast: A Case Series.

Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall” Reaction.

Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution

Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.

Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.

Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65

Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).

Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only